Cargando…
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune system. Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has produced unparalleled, durable clinical responses, with highes...
Autores principales: | Lau, Janet, Cheung, Jeanne, Navarro, Armando, Lianoglou, Steve, Haley, Benjamin, Totpal, Klara, Sanders, Laura, Koeppen, Hartmut, Caplazi, Patrick, McBride, Jacqueline, Chiu, Henry, Hong, Rebecca, Grogan, Jane, Javinal, Vincent, Yauch, Robert, Irving, Bryan, Belvin, Marcia, Mellman, Ira, Kim, Jeong M., Schmidt, Maike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321797/ https://www.ncbi.nlm.nih.gov/pubmed/28220772 http://dx.doi.org/10.1038/ncomms14572 |
Ejemplares similares
-
Microenvironmental regulation of tumour immunity and response to immunotherapy
por: Kockx, Mark M, et al.
Publicado: (2021) -
MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013) -
TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018) -
The effect of gold salts on tumour immunity and its stimulation by Corynebacterium Parvum.
por: McBride, W. H., et al.
Publicado: (1975) -
SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer
por: Viotti, Manuel, et al.
Publicado: (2018)